HC Wainwright Issues Optimistic Forecast for ATOS Earnings

Atossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Stock analysts at HC Wainwright lifted their Q1 2025 earnings per share estimates for Atossa Therapeutics in a research report issued on Tuesday, March 25th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.05) for the quarter, up from their previous estimate of ($0.07). HC Wainwright has a "Buy" rating and a $7.00 price target on the stock. The consensus estimate for Atossa Therapeutics' current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Therapeutics' Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.30) EPS, FY2028 earnings at ($0.22) EPS and FY2029 earnings at ($0.18) EPS.

Separately, Ascendiant Capital Markets raised their price objective on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a "buy" rating in a research note on Monday, December 9th.

Atossa Therapeutics Price Performance

Shares of Atossa Therapeutics stock traded down $0.01 during trading on Friday, hitting $0.67. The stock had a trading volume of 260,886 shares, compared to its average volume of 980,999. Atossa Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.31. The firm's fifty day simple moving average is $0.79 and its 200-day simple moving average is $1.09. The stock has a market cap of $85.90 million, a PE ratio of -3.02 and a beta of 1.20.

Remove Ads

Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last issued its quarterly earnings results on Tuesday, March 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC bought a new position in Atossa Therapeutics in the 3rd quarter worth about $29,000. The Manufacturers Life Insurance Company bought a new position in Atossa Therapeutics in the third quarter worth approximately $75,000. State Street Corp increased its holdings in Atossa Therapeutics by 4.2% during the 3rd quarter. State Street Corp now owns 1,732,221 shares of the company's stock worth $2,633,000 after purchasing an additional 69,180 shares during the period. XTX Topco Ltd raised its position in Atossa Therapeutics by 101.2% during the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company's stock valued at $75,000 after purchasing an additional 24,951 shares in the last quarter. Finally, Barclays PLC lifted its holdings in shares of Atossa Therapeutics by 280.9% in the 3rd quarter. Barclays PLC now owns 167,718 shares of the company's stock worth $255,000 after buying an additional 123,683 shares during the period. Hedge funds and other institutional investors own 12.74% of the company's stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.